Benzothia(DIA)zepine compounds for treatment of hbv and hdv

HK40137367APending Publication Date: 2026-09-11ASSEMBLY BIOSCIENCES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026124712
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-23
Filing Date
2026-06-11
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure provides, in part, benzothia(dia)zepine compounds, and pharmaceutical compositions thereof, and methods of treating Hepatitis B virus (HBV) and Hepatitis D virus (HDV) infections.
Need to check novelty before this filing date? Find Prior Art

Description

Abstract This invention discloses benzothiazole (diazazo) compounds and pharmaceutical compositions thereof, as well as methods for treating hepatitis B virus (HBV) and hepatitis D virus (HDV) infections.

Claims

CLAIMS:

1. A compound of Formula II, or a pharmaceutically acceptable salt thereof, wherein: M is -CHF-, -CH(CH3)-, -CF(CH3)-, -CF2-, or -C(CH3)2-; Ra, Rband Rcare independently selected for each occurrence from the group consisting of hydrogen, C1-6alkyl, haloC1-6alkyl and C3-6monocycloalkyl; R1is OH, CH3, -C(O)NH2, -C(O)OH, -C(O)OC1-6alkyl, -P(O)(OH)2, -S(O)2OH orR2aand R2bare independently selected from the group consisting of hydrogen, halo, OH, methyl, ethyl and CH2OH; or R2aand R2btogether with the carbon atom to which they are attached form a C=CH2, C3-6monocycloalkyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl or 1,3-dioxanyl group, wherein the C3-6monocycloalkyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl or 1,3-dioxanyl group is optionally substituted with 1 to 3 independently selected from halo and methyl groups; R3is selected from the group consisting of hydrogen, halogen, cyano, RaRbN-, C1-4alkyl, haloC1-4alkyl, C1-4alkoxy, haloC1-4alkoxy, C1-4alkylthio, haloC1-4alkylthio, C3-7monocycloalkyl, C3-7monocycloalkyloxy, C3-7monocycloalkylthio, C3-7monocycloalkyl- CH2-thio, and C5-12bicycloalkylthio, wherein the C3-7monocycloalkyl, C3-7monocycloalkyloxy, C3-7monocycloalkylthio, C3-7monocycloalkyl-CH2-thio, and C5-12bicycloalkylthio group is optionally substituted with 1 to 3 halo groups; R4is haloC3-4alkyl; R5is phenyl, C3-7monocycloalkyl or C5-12bicycloalkyl, wherein the phenyl, C3-7monocycloalkyl or C5-12bicycloalkyl is optionally substituted with one to six substituentsindependently selected form the group consisting of halo, OH, CN, HOC(O)-, RaRbN-, RaRbNS(O)q-, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, haloC1-4alkyl, hydroxyC1-4alkyl-, RaRbNC1-4alkyl-, C1-4alkoxy, haloC1-4alkoxy, hydroxyC1-4alkoxy-, RaRbNC1-4alkoxy-, C1-3alkoxyC1-4alkyl-, haloC1-3alkoxyC1-4alkyl-, RaRbNC(O)-, C1-4alkylC(O)-, C1-4alkoxyC(O)-, C1-4alkylC(O)O-, C1-4alkylS(O)q-, C1-4alkylS(O)qNRc-, C1-6alkylS(O)qC1-4alkyl-, C1-4alkylC(O)C1-6alkyl-, and C1-6alkylC(O)OC1-4alkyl-; and q is independently selected for each occurrence from the group consisting of 0, 1 and 2.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein M is -CHF-.

3. The compound of claim 1 or 2, wherein Formula II is of Formula IIa, or a pharmaceutically acceptable salt thereof.

4. The compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R1is -C(O)OH.

5. The compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R1is -S(O)2OH.

6. The compound according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein R1is -P(O)(OH)2,7. The compound according to any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein R2aand R2bare independently selected from the group consisting of hydrogen, halo, OH and methyl.

8. The compound according to any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein R2aand R2bare methyl.

9. The compound according to any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein R2ais hydrogen and R2bare methyl.

10. The compound according to any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein R2aand R2btogether with the carbon atom to which they are attached form a C=CH2, cyclopropyl, cyclobutyl, or oxetanyl group, wherein the cyclopropyl or cyclobutyl group is optionally substituted with 1-3 halo groups.

11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein R2aand R2btogether with the carbon atom to which they are attached form a C=CH2, cyclopropyl, cyclobutyl, or oxetanyl group.

12. The compound of claim 11, or a pharmaceutically acceptable salt thereof, wherein R2aand R2btogether with the carbon atom to which they are attached form a cyclopropyl group.

13. The compound according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R3is haloC1-2alkyl.

14. The compound of claim 13, or a pharmaceutically acceptable salt thereof, wherein R3is CF3.

15. The compound according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R3is C5-12bicycloalkylthio.

16. The compound according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R3is haloC3-7monocycloalkylthio.

17. The compound according to any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R4is n-butyl substituted with 1 to 6 halo atoms.

18. The compound of claim 17, or a pharmaceutically acceptable salt thereof, wherein R4is n-butyl substituted with 1 to 6 F atoms.

19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein R4is -CH2CH2CF2CH3.

20. The compound according to any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein R4is n-propyl substituted with 1 to 6 halo atoms.

21. The compound of claim 20, or a pharmaceutically acceptable salt thereof, wherein R4is n-propyl substituted with 1 to 6 F atoms.

22. The compound of claim 21, or a pharmaceutically acceptable salt thereof, wherein R4is -CH2CH2CF3.

23. The compound according to any one of claims 1-22, or a pharmaceutically acceptable salt thereof, wherein R5is C3-7monocycloalkyl optionally substituted with one to six substituents independently selected form the group consisting of halo, OH, CN, HOC(O)-, RaRbN-, RaRbNS(O)q-, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, haloC1-4alkyl, hydroxyC1-4alkyl-, RaRbNC1-4alkyl-, C1-4alkoxy, haloC1-4alkoxy, hydroxyC1-4alkoxy-, RaRbNC1-4alkoxy-, C1-3alkoxyC1-4alkyl-, haloC1-3alkoxyC1-4alkyl-, RaRbNC(O)-, C1-4alkylC(O)-, C1-4alkoxyC(O)-,C1-4alkylC(O)O-, C1-4alkylS(O)q-, C1-4alkylS(O)qNRc-, C1-6alkylS(O)qC1-4alkyl-, C1-4alkylC(O)C1-6alkyl-, and C1-6alkylC(O)OC1-4alkyl-.

24. The compound of claim 23, or a pharmaceutically acceptable salt thereof, wherein25. The compound according to an one of claims 1- 22, or a pharmaceutically acceptable salt thereof, wherein In certain embodiments, R5is phenyl optionally substituted with one to six substituents independently selected form the group consisting of halo, OH, CN, HOC(O)-, RaRbN-, RaRbNS(O)q-, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, haloC1-4alkyl, hydroxyC1-4alkyl-, RaRbNC1-4alkyl-, C1-4alkoxy, haloC1-4alkoxy, hydroxyC1-4alkoxy-, RaRbNC1-4alkoxy-, C1-3alkoxyC1-4alkyl-, haloC1-3alkoxyC1-4alkyl-, RaRbNC(O)-, C1-4alkylC(O)-, C1-4alkoxyC(O)-, C1-4alkylC(O)O-, C1-4alkylS(O)q-, C1-4alkylS(O)qNRc-, C1-6alkylS(O)qC1-4alkyl-, C1-4alkylC(O)C1-6alkyl-, and C1-6alkylC(O)OC1-4alkyl-.

26. The compound of claim 25, or a pharmaceutically acceptable salt thereof, wherein27. The compound of claim 25, or a pharmaceutically acceptable salt thereof, wherein R5is28. A pharmaceutical composition comprising a compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

29. A method of treating Hepatitis B (HBV) infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof.

30. A method of treating Hepatitis B (HBV) infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 28.

31. A method of treating Hepatitis D (HDV) infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof.

32. A method of treating Hepatitis D (HDV) infection in a subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 28.

33. A compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof, for use in therapy.

34. A compound according to any one of claims 1-27, or a pharmaceutically acceptable salt thereof, for use as a medicament.